Cargando…

Pulmonary hypertension experience in an expert university hospital

OBJECTIVE: Pulmonary artery hypertension (PAH) is characterized by remodeling of the small pulmonary arteries, leading to a progressive increase in pulmonary vascular resistance and right ventricular failure. In this study, we aimed to share our 10 years of experience dealing with pulmonary hyperten...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinan, Ümit Yaşar, Demir, Rengin, Canbolat, İsmail Polat, Palabıyık, Mert, Kaya, Ayşem, Küçükoğlu, Mehmet Serdar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237787/
https://www.ncbi.nlm.nih.gov/pubmed/29952361
http://dx.doi.org/10.14744/AnatolJCardiol.2018.60252
_version_ 1783371240523694080
author Sinan, Ümit Yaşar
Demir, Rengin
Canbolat, İsmail Polat
Palabıyık, Mert
Kaya, Ayşem
Küçükoğlu, Mehmet Serdar
author_facet Sinan, Ümit Yaşar
Demir, Rengin
Canbolat, İsmail Polat
Palabıyık, Mert
Kaya, Ayşem
Küçükoğlu, Mehmet Serdar
author_sort Sinan, Ümit Yaşar
collection PubMed
description OBJECTIVE: Pulmonary artery hypertension (PAH) is characterized by remodeling of the small pulmonary arteries, leading to a progressive increase in pulmonary vascular resistance and right ventricular failure. In this study, we aimed to share our 10 years of experience dealing with pulmonary hypertension (PH) and provide information in real-life settings in terms of demographics, clinical course, PH subgroup distribution, and treatment patterns in patients with PAH in a tertiary center. METHODS: In this retrospective, single-center, observational study, we screened the patients who applied to PH outpatient clinic of İstanbul University Institute of Cardiology due to the suspicion of PAH between 2008 and 2017. While group 1, 4, and 5 PH patients were included, group 2 and 3 PH patients were excluded from the study. RESULTS: Our study group comprised 162 patients (115 females, 71%). The female: male ratio was 2.4. The mean age was 52±16 years. Most (86.4%) of the patients were in group 1 PH (PAH). The rest (13.6%, n=22) of the patients were in group 4 PH (chronic thromboembolic PH). In group 1 PH, 45.7% of patients (n=64) were classified as having idiopathic PAH (IPAH) after excluding the alternative diagnosis using PH diagnostic algorithm. The remaining 54.3% of group 1 PH patients (n=76) had various diseases that caused PAH, which is called associated PAH (APAH); APAH group included PAH associated with congenital heart diseases (n=70), connective tissue disorders (scleroderma, n=4) and portal hypertension (n=2). CONCLUSION: Our data provides important information in real-life settings in terms of demographics, clinical course, PH subgroup distribution, and treatment patterns in patients with PAH in a reference tertiary center in Turkey.
format Online
Article
Text
id pubmed-6237787
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-62377872018-11-19 Pulmonary hypertension experience in an expert university hospital Sinan, Ümit Yaşar Demir, Rengin Canbolat, İsmail Polat Palabıyık, Mert Kaya, Ayşem Küçükoğlu, Mehmet Serdar Anatol J Cardiol Original Investigation OBJECTIVE: Pulmonary artery hypertension (PAH) is characterized by remodeling of the small pulmonary arteries, leading to a progressive increase in pulmonary vascular resistance and right ventricular failure. In this study, we aimed to share our 10 years of experience dealing with pulmonary hypertension (PH) and provide information in real-life settings in terms of demographics, clinical course, PH subgroup distribution, and treatment patterns in patients with PAH in a tertiary center. METHODS: In this retrospective, single-center, observational study, we screened the patients who applied to PH outpatient clinic of İstanbul University Institute of Cardiology due to the suspicion of PAH between 2008 and 2017. While group 1, 4, and 5 PH patients were included, group 2 and 3 PH patients were excluded from the study. RESULTS: Our study group comprised 162 patients (115 females, 71%). The female: male ratio was 2.4. The mean age was 52±16 years. Most (86.4%) of the patients were in group 1 PH (PAH). The rest (13.6%, n=22) of the patients were in group 4 PH (chronic thromboembolic PH). In group 1 PH, 45.7% of patients (n=64) were classified as having idiopathic PAH (IPAH) after excluding the alternative diagnosis using PH diagnostic algorithm. The remaining 54.3% of group 1 PH patients (n=76) had various diseases that caused PAH, which is called associated PAH (APAH); APAH group included PAH associated with congenital heart diseases (n=70), connective tissue disorders (scleroderma, n=4) and portal hypertension (n=2). CONCLUSION: Our data provides important information in real-life settings in terms of demographics, clinical course, PH subgroup distribution, and treatment patterns in patients with PAH in a reference tertiary center in Turkey. Kare Publishing 2018-07 2018-06-11 /pmc/articles/PMC6237787/ /pubmed/29952361 http://dx.doi.org/10.14744/AnatolJCardiol.2018.60252 Text en Copyright: © 2018 Turkish Society of Cardiology http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Original Investigation
Sinan, Ümit Yaşar
Demir, Rengin
Canbolat, İsmail Polat
Palabıyık, Mert
Kaya, Ayşem
Küçükoğlu, Mehmet Serdar
Pulmonary hypertension experience in an expert university hospital
title Pulmonary hypertension experience in an expert university hospital
title_full Pulmonary hypertension experience in an expert university hospital
title_fullStr Pulmonary hypertension experience in an expert university hospital
title_full_unstemmed Pulmonary hypertension experience in an expert university hospital
title_short Pulmonary hypertension experience in an expert university hospital
title_sort pulmonary hypertension experience in an expert university hospital
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237787/
https://www.ncbi.nlm.nih.gov/pubmed/29952361
http://dx.doi.org/10.14744/AnatolJCardiol.2018.60252
work_keys_str_mv AT sinanumityasar pulmonaryhypertensionexperienceinanexpertuniversityhospital
AT demirrengin pulmonaryhypertensionexperienceinanexpertuniversityhospital
AT canbolatismailpolat pulmonaryhypertensionexperienceinanexpertuniversityhospital
AT palabıyıkmert pulmonaryhypertensionexperienceinanexpertuniversityhospital
AT kayaaysem pulmonaryhypertensionexperienceinanexpertuniversityhospital
AT kucukoglumehmetserdar pulmonaryhypertensionexperienceinanexpertuniversityhospital